stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
63.82
1.90
+3.07%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Operating cash flow
Vaxcyte, Inc.'s operating cash flow for fiscal 2025 was −$655.6M, compared with −$452.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$881.2M. Over the past ten years it has ranged from −$655.6M (fiscal 2025) to −$30.5M (fiscal 2018) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Vaxcyte, Inc. ranks 601st of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$655.6M | — |
| FY2024 | −$452.6M | — |
| FY2023 | −$296.8M | — |
| FY2022 | −$170.6M | — |
| FY2021 | −$121.4M | — |
| FY2020 | −$46.6M | — |
| FY2019 | −$47.1M | — |
| FY2018 | −$30.5M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$232.5M | — |
| Mar 2026 | −$280.6M | — |
| Dec 2025 | −$224.8M | — |
| Sep 2025 | −$143.3M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$655.6M
High −$30.5M
Ten-year median
−$146.0M
Current reading's percentile
13
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $676.6M |
| TECH Bio-Techne Corp compare | $292.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$157.0M |
| IBRX ImmunityBio, Inc. compare | −$281.1M |
| PCVX Vaxcyte, Inc. | −$881.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item